多西他赛联合替吉奥胶囊治疗晚期食管癌的效果  

Effect of Docetaxel combined with Tigueo Capsules in the treatment of advanced esophageal cancer

作　　者：陈胜佳[1] 朱凯[1] 林金兰[1] 张晶[1] 徐振武[1] 蒋侃[1] 苗茜[1] CHEN Sheng-jia;ZHU Kai;LIN Jin-lan;ZHANG Jin;XU Zhen-wu;JIANG Kan;MIAO Qian(Department of Chest Physicians,Fujian Provincial Cancer Hospital,Fujian Province,Fuzhou 350001,China)

机构地区：[1]福建省肿瘤医院胸部内科,福建福州350001

出　　处：《中国当代医药》2018年第32期78-80,共3页China Modern Medicine

摘　　要：目的探讨多西他赛联合替吉奥胶囊治疗晚期食管癌的临床效果。方法选取2016年1月~2017年1月我院收治的80例晚期食管癌患者作为研究对象,以随机数字表法将其分为观察组与对照组,每组各40例。观察组患者提供多西他赛联合替吉奥胶囊治疗,对照组患者采用紫杉醇联合氟尿嘧啶化疗。比较两组患者的临床疗效、不良反应及生存期。结果观察组有1例完全缓解,22例部分缓解,7例稳定,10例进展,总有效率为57.5%。对照组有14例部分缓解,9例稳定,17例进展,总有效率为35.0%。观察组患者的总有效率高于对照组,差异有统计学意义(P<0.05)。两组患者出现不同程度的脱发、恶心呕吐、腹泻等不良反应,两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。观察组患者的总生存期和无进展生存期(PFS)均长于对照组,差异有统计学意义(P<0.05)。结论采用多西他赛联合替吉奥胶囊治疗晚期食管癌患者的效果较好,能够改善患者的生存质量,控制不良反应,具有很高的应用价值。Objective To investigate the clinical effect of Docetaxel combined with Tigueo Capsules in the treatment of advanced esophageal carcinoma. Methods From January 2016 to January 2017, 80 patients with advanced esophageal cancer were selected and randomly divided into observation group and control group, 40 cases in each group. The patients in observation group were treated with Docetaxel combined with Tigueo Capsules. The patients in the control group were treated with Paclitaxel combined with Fluorouracil chemotherapy. The clinical adverse reactions and survival time were compared between the two groups. Results In the observation group, there was 1 case of complete remission, 22 cases of partial remission, 7 cases of stability and 10 cases of progress, with the total effective rate of57.5%. In the control group, there were 14 cases of partial remission, 9 cases of stability and 17 cases of progress, with a total effective rate of 35.0%. The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant（P〈0.05）. The two groups of patients showed different degree of alopecia, nausea and vomiting, diarrhea and other adverse reactions. There was no statistically significant difference in the incidence of adverse reactions between the two groups（P〉0.05）. The total survival and progression free survival（PFS）were longer in the observation group than in the control group, the differences were statistically significant（P〈0.05）.Conclusion Docetaxel combined with Tigueo Capsules is effective in the treatment of patients with advanced esophageal cancer and can improve their quality of life. It can control adverse reactions and has high application value.

关 键 词：多西他赛 替吉奥胶囊 晚期食管癌 不良反应 

分 类 号：R735.1[医药卫生—肿瘤]